These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8525689)

  • 1. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group.
    Kuter BJ; Ngai A; Patterson CM; Staehle BO; Cho I; Matthews H; Provost PJ; White CJ
    Vaccine; 1995 Aug; 13(11):967-72. PubMed ID: 8525689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children.
    Ngai AL; Staehle BO; Kuter BJ; Cyanovich NM; Cho I; Matthews H; Keller P; Arvin AM; Watson B; White CJ
    Pediatr Infect Dis J; 1996 Jan; 15(1):49-54. PubMed ID: 8684876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children.
    Shinefield HR; Black SB; Staehle BO; Matthews H; Adelman T; Ensor K; Li S; Chan I; Heyse J; Waters M; Chan CY; Vessey SJ; Kaplan KM; Kuter BJ;
    Pediatr Infect Dis J; 2002 Jun; 21(6):555-61. PubMed ID: 12182381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of Bio Pox™, a live varicella vaccine (Oka strain) in Indian children: A comparative multicentric, randomized phase II/III clinical trial.
    Dubey AP; Faridi MMA; Mitra M; Kaur IR; Dabas A; Choudhury J; Mukherjee M; Mishra D
    Hum Vaccin Immunother; 2017 Sep; 13(9):2032-2037. PubMed ID: 28509605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy infants, children, and adolescents.
    Paradis EM; Tikhonov O; Cao X; Kharit SM; Fokin A; Platt HL; Wittke F; Jotterand V
    Hum Vaccin Immunother; 2021 Nov; 17(11):4183-4189. PubMed ID: 34702124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy adults.
    Paradis EM; Tikhonov O; Cao X; Kharit SM; Fokin A; Platt HL; Banniettis N
    Hum Vaccin Immunother; 2021 Nov; 17(11):4177-4182. PubMed ID: 34473594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of subcutaneous versus intramuscular Oka/Merck varicella vaccination in healthy children.
    Dennehy PH; Reisinger KS; Blatter MM; Veloudis BA
    Pediatrics; 1991 Sep; 88(3):604-7. PubMed ID: 1881743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flexibility in the administration schedule of varicella vaccination in healthy adolescents and young adults.
    Kosuwon P; Wasi C; Sutra S; Kositanont U; Hutagalung Y; Bock HL
    Asian Pac J Allergy Immunol; 2002 Dec; 20(4):241-5. PubMed ID: 12744625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children.
    Lau YL; Vessey SJ; Chan IS; Lee TL; Huang LM; Lee CY; Lin TY; Lee BW; Kwan K; Kasim SM; Chan CY; Kaplan KM; Distefano DJ; Harmon AL; Golie A; Hartzel J; Xu J; Li S; Matthews H; Sadoff JC; Shaw A
    Vaccine; 2002 Jul; 20(23-24):2942-9. PubMed ID: 12126906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live attenuated varicella virus vaccine. Efficacy trial in healthy children.
    Weibel RE; Neff BJ; Kuter BJ; Guess HA; Rothenberger CA; Fitzgerald AJ; Connor KA; McLean AA; Hilleman MR; Buynak EB
    N Engl J Med; 1984 May; 310(22):1409-15. PubMed ID: 6325909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Live attenuated varicella vaccine in healthy 12- to 24-month-old children.
    Johnson CE; Shurin PA; Fattlar D; Rome LP; Kumar ML
    Pediatrics; 1988 Apr; 81(4):512-8. PubMed ID: 2832819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten year follow-up of healthy children who received one or two injections of varicella vaccine.
    Kuter B; Matthews H; Shinefield H; Black S; Dennehy P; Watson B; Reisinger K; Kim LL; Lupinacci L; Hartzel J; Chan I;
    Pediatr Infect Dis J; 2004 Feb; 23(2):132-7. PubMed ID: 14872179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age.
    Silber JL; Chan IS; Wang WW; Matthews H; Kuter BJ
    Pediatr Infect Dis J; 2007 Jul; 26(7):572-6. PubMed ID: 17596796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine.
    Sperber SJ; Smith BV; Hayden FG
    Antiviral Res; 1992 Mar; 17(3):213-22. PubMed ID: 1314536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9-24 months.
    Ramkissoon A; Coovadia HM; Jugnundan P; Haffejee IE; Meurice F; Vandevoorde D
    S Afr Med J; 1995 Dec; 85(12):1295-8. PubMed ID: 8600589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of single dose live attenuated varicella vaccine (VR 795 Oka strain) in healthy Indian children: a randomized controlled study.
    Mitra M; Faridi M; Ghosh A; Shah N; Shah R; Chaterjee S; Narang M; Bhattacharya N; Bhat G; Choudhury H; Kadhe G; Mane A; Roy S
    Hum Vaccin Immunother; 2015; 11(2):443-9. PubMed ID: 25692656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial of the Oka strain of live attenuated varicella vaccine on healthy children.
    Ozaki T; Matsui T; Ichikawa T; Asano Y; Yamanishi K; Takahashi M
    Biken J; 1984 Sep; 27(2-3):39-42. PubMed ID: 6100056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of a live-attenuated varicella vaccine in a healthy population aged 13 years and older: A randomized, double-blind, controlled study.
    Huang L; Chen Z; Song Y; Tan J; Jia N; You W; Yuan H; Feng G; Li C; Luan C; Quan Y; Wang Y
    Vaccine; 2024 Jan; 42(2):396-401. PubMed ID: 38057208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of decreasing amounts of live virus, while antigen content remains constant, on immunogenicity of Oka/Merck varicella vaccine.
    Watson B; Piercy S; Soppas D; Browngoehl K; Warner M; Isganitis K; White CJ; Kuter B; Chua J; Starr S
    J Infect Dis; 1993 Dec; 168(6):1356-60. PubMed ID: 8245520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX®.
    Reisinger KS; Richardson E; Malacaman EA; Levin MJ; Gardner JL; Wang W; Stek JE; Kuter B
    Vaccine; 2019 Sep; 37(38):5788-5795. PubMed ID: 30146405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.